eIF4E is a component of the eIF4F . 01 Apr 2021 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (PO) (NCT04622007) An Open-label Study Examining the Effect of Tomivosertib (eFT508) in ... SAN DIEGO and REDWOOD CITY, Calif., June 05, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors ("STRIs") for the treatment of cancer, today reported positive interim results of the company's ongoing Phase 1/2 clinical trial of eIF4A inhibitor . Tomivosertib (10 mg/kg i.p ~50 μL) or vehicle was then injected, and 1 h later all mice were tested twice more, and their scores were averaged. National Cancer Institute Safety and Feasibility of Radiotherapy Plus ... - The Oncologist eFFECTOR Initiates Dosing of eFT508 (tomivosertib) in a Phase 2 Add-on ... Previously received investigational product in a clinical trial within 30 days or within 5 elimination half-lives (whichever is longer) prior to the start of Tomivosertib (eFT-508), or is planning to take part in another clinical trial while participating in this study; Our study provides pre-clinical evidence to initialize clinical trials for gastric cancer using tomivosertib in combination with chemotherapy. A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With . Tyler Research and Clinical Trials | Texas Oncology eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin ... Researchers in this study believe that Tomivosertib, a highly selective MNK1/2 inhibitor (currently undergoing clinical trials for the treatment of patients with advanced solid tumors and lymphomas), . eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin ... A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy: Actual Study Start Date : June 2, 2021: Estimated Primary Completion Date : March 15, 2024: Estimated Study Completion Date : Phase 2 Breast Cancer Trial to Test Keytruda, Tomivosertib Combination Zotatifin is a potent and sequence-selective small molecule inhibitor of eIF4A that is designed to supress expression of a network of cancer driving proteins, including Cyclins D and E, CDKs 2, 4 and 6 and select RTKs as well as KRAS. DB15219. eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced publication in the peer reviewed journal Nature Medicine of preclinical research demonstrating that tomivosertib (eFT508), the company's oral, selective, small molecule inhibitor of MNK1/2, selectively inhibits expression of the programed-death . . About UC Irvine Clinical Trials. eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin ... eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin ... The leading candidate, tomivosertib, is the subject of two Phase 2 studies featuring two . Tomivosertib (10 mg/kg i.p ~50 μL) or vehicle was then injected, and 1 h later all mice were tested twice more, and their scores were averaged. PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL. 2 'Strong Buy' Stocks That Could Be Bought Out, According to Credit ... Tomivosertib (eFT508) is a potent, highly selective, and orally active MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin ... This Phase 2, open-label study will evaluate the safety, tolerability, antitumor activity, and pharmacokinetics (PK) of Tomivosertib (eFT-508) in subjects who have initiated anti-PD-1/anti-PD-L1 monotherapy and either developed progressive disease (PD) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 on therapy or have undergone 12 weeks of anti-PD-1/anti-PD-L1 therapy with no . eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity It potentially results in decreased tumor cell proliferation and tumor growth. UC Irvine Lung Cancer Trial → Tomivosertib Combined With Pembrolizumab ... In December 2021, Biotheus Inc. announced that its proprietary anti-PD-L1/TGF-β bifunctional therapeutic, named PM8001, has been approved by the USFDA (United States Food and Drug Administration . Tomivosertib (eFT508) is one of the molecules with such scaffold. Protocol No. Naïve mice were trained for 1 trial, and then 2 baseline trials were conducted and scores for both trials were averaged. eFFECTOR Therapeutics Announces Clinical Collaboration with ... - BioSpace Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. . Clinical Trial on Breast Cancer: tomivosertib, paclitaxel - ICH GCP Researchers in this study believe that Tomivosertib, a highly selective MNK1/2 inhibitor (currently undergoing clinical trials for the treatment of patients with advanced solid tumors and lymphomas), . Our lead product candidate, tomivosertib, is an oral small molecule inhibitor of MNK. Clinical Trial: NCT04261218 - My Cancer Genome SAN DIEGO, July 16, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors ("STRIs") for the treatment of cancer, announced today the publication of data highlighting the role of eukaryotic translation initiation factor 4E ("eIF4E"), in the peer-reviewed journal Cell Reports. Annapolis, MD. We thank Jiangsu HengRui Medicine Co., China, for kindly providing the anti-PD-1 antibody camrelizumab. Tomivosertib Completed Phase 2 Trials for Castration Resistant Prostate Cancer Treatment. It is one of the first two Mnk inhibitors that entered clinical trials, and has displayed momentous activity against several solid and hematological cancers. Our trial will determine if the potent MNK inhibitor, tomivosertib, controls tumor growth either directly or by enhancing anti-tumor immunity. Phase 2 Trial of Tomivosertib Begins Dosing Advanced... eFFECTOR's lead product candidate, tomivosertib, is a MNK . . Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) NCT04622007. Medicine Demonstrates Immunological Effects of Tomivosertib Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy ... 2021-11-08 | NDAQ:EFTR | Press Release - stockhouse The time until each animal fell was recorded for each trial. Pipeline | eFFECTOR Current Clinical Trials; EFT508-0011; Navigation. KICKSTART is a randomized, double-blind, placebo-controlled clinical trial assessing the efficacy and safety of tomivosertib in combination with pembrolizumab, a U.S. Food and Drug Administration (FDA)-approved PD-1 inhibitor, as frontline combination therapy or as an extension of frontline therapy at the first radiographic progression of . eFFECTOR Therapeutics Reports First Quarter 2022 Financial ... - BioSpace In addition, zotatifin is being evaluated in a Phase 1b clinical trial as an antiviral agent in patients with mild to moderate COVID-19 infections. National Cancer Institute Tomivosertib. SAN DIEGO and REDWOOD CITY, Calif., June 05, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors ("STRIs") for the treatment of cancer, today reported positive interim results of the company's ongoing Phase 1/2 clinical trial of eIF4A inhibitor zotatifin in patients with solid tumors that showed .